The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Remdesivir for the Treatment of Covid-19 — Final Report
Open accessAbstract
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,258 · cited 4×
“The trial site in South Korea received funding from the Seoul National University Hospital.”
InfluentialWang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,442
Sheahan, T. P., Sims, A. M., Leist, S. R., Schäfer, A., Won, J. J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D. M., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,757
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575 · cited 3×
“There were 60 trial sites and 13 subsites in the United States (45 sites), Denmark (8), the United Kingdom (5), Greece (4), Germany (3), Korea (2), Mexico (2), Spain (2), Japan (1), and Singapore (1).”
Agostini, M. L., Andres, E. L., Sims, A. M., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,418
Spinner, C. D., Gottlieb, R., Criner, G. J., Arribas, J. R., Cattelan, A. M., Soriano, À., Ogbuagu, O. E., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,234
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D. P., Cihlář, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 888
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,018
Jassat, W., Mudara, C., Ozougwu, L., Tempia, S., Blumberg, L. H., Davies, M., Pillay, Y. G., Carter, T., Morewane, R., Wolmarans, M., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00289-8 · Cited by 197
Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19
Bridges, J. P., Vladar, E. K., Huang, H., & Mason, R. J. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217561 · Cited by 162
Roth, G. A., Emmons-Bell, S., Alger, H. M., Bradley, S. M., Das, S. R., de Lemos, J. A., Gakidou, E., Elkind, M. S. V., Hay, S., Hall, J. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8828 · Cited by 145
Gordon, J. M., Magbee, T., & Yoder, L. H. (2021) · Applied Nursing Research · doi:10.1016/j.apnr.2021.151418 · Cited by 189
Kalil, A. C., Mehta, A. K., Patterson, T. F., Erdmann, N., Gómez, C. A., Jain, M. K., Wolfe, C. R., Ruiz-Palacios, G. M., Kline, S., Pineda, J. R., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00384-2 · Cited by 160
Lightner, A. L., Sengupta, V., Qian, S., Ransom, J. T., Suzuki, S., Park, D. J., Melson, T. I., Williams, B. P., Walsh, J. J., & Awili, M. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.06.024 · Cited by 166
Rabaan, A. A., Al-Ahmed, S. H., Sah, R., Tiwari, R., Yatoo, M. I., Patel, S. K., Pathak, M., Malik, Y. S., Dhama, K., Singh, K. P., et al. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00384-w · Cited by 157
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics
Gomes, C. P., Fernandes, D. E., da Fonseca, F. M. C., da Mata, G. F., Riguetti, M. T. P., Varela, P., Kirsztajn, G. M., & Pesquero, J. B. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.589505 · Cited by 162
Belli, L. S., Fondevila, C., Cortesi, P. A., Conti, S., Karam, V. H., Adam, R. A., Coilly, A., Ericzon, B. G., Loinaz, C., Cuervas‐Mons, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.11.045 · Cited by 156
Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008461 · Cited by 152
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
Zhao, Y., Du, X., Duan, Y., Pan, X., Sun, Y., You, T., Han, L., Jin, Z., Shang, W., Yu, J., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00836-9 · Cited by 155
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
Rahmani, H. R., Davoudi-Monfared, E., Nourian, A., Khalili, H., Hajizadeh, N., Jalalabadi, N. Z., Fazeli, M. R., Ghazaeian, M., & Yekaninejad, M. S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106903 · Cited by 153
Fried, M. W., Crawford, J. M., Mospan, A. R., Watkins, S. E., Muñoz, B., Zink, R. C., Elliott, S., Burleson, K., Landis, C. S., Reddy, K. R., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1268 · Cited by 155
Flavonoids are promising safe therapy against COVID-19
Alzaabi, M. M., Hamdy, R., Ashmawy, N. S., Hamoda, A. M., Alkhayat, F., Khademi, N. N., Joud, S. M. A. A., El‐Keblawy, A. A., & Soliman, S. S. M. (2021) · Phytochemistry Reviews · doi:10.1007/s11101-021-09759-z · Cited by 166
Novel insights on the pulmonary vascular consequences of COVID-19
Potus, F., Mai, V., Lebret, M., Malenfant, S., Breton-Gagnon, É., Lajoie, A. C., Boucherat, O., Bonnet, S., & Provencher, S. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00195.2020 · Cited by 160
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Boras, B., Jones, R. M., Anson, B. J., Arenson, D., Aschenbrenner, L., Bakowski, M. A., Beutler, N., Binder, J., Chen, E., Eng, H., et al. (2020) · doi:10.1101/2020.09.12.293498 · Cited by 154
Natural history of COVID-19 and therapeutic options
Gautret, P., Million, M., Jarrot, P., Camoin‐Jau, L., Colson, P., Fenollar, F., Léone, M., Scola, B. L., Devaux, C. A., Gaubert, J. Y., et al. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1847640 · Cited by 158
Cenko, E., Badimón, L., Bugiardini, R., Claeys, M. J., Luca, G. D., de Wit, C., Dérumeaux, G., Dorobanţu, M., Duncker, D. J., Eringa, E. C., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab298 · Cited by 152
COVID-19 and antimicrobial resistance: A cross-study
Rizvi, S. G., & Ahammad, S. Z. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.150873 · Cited by 151
Deciphering the state of immune silence in fatal COVID-19 patients
Bost, P., Sanctis, F. D., Canè, S., Ugel, S., Donadello, K., Castellucci, M., David, E., Fiore, A., Anselmi, C., Barouni, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21702-6 · Cited by 148
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 150
COVID ‐19: immunopathology, pathophysiological mechanisms, and treatment options
van Eijk, L. E., Binkhorst, M., Bourgonje, A. R., Offringa, A. K., Mulder, D. J., Bos, E. M., Kolundžić, N., Abdulle, A. E., van der Voort, P. H. J., Rikkert, M. G. M. O., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5642 · Cited by 156
Chai, K. L., Valk, S. J., Piechotta, V., Kimber, C., Monsef, I., Doree, C. J., Wood, E. M., Lamikanra, A., Roberts, D. J., McQuilten, Z., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub3 · Cited by 150
Oliveira, E., Parikh, A., LOPEZ‐RUIZ, A. F., Carrilo, M., Goldberg, J., Cearras, M., Fernainy, K., Andersen, S., Mercado, L., Guan, J., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249038 · Cited by 146
Challenges for Drug Repurposing in the COVID-19 Pandemic Era
Sultana, J., Crisafulli, S., Gabbay, F., Lynn, E., Shakir, S., & Trifirò, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588654 · Cited by 156
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Kreuzberger, N., Hirsch, C., Chai, K. L., Tomlinson, E., Khosravi, Z., Popp, M., Neidhardt, M., Piechotta, V., Salomon, S., Valk, S. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013825.pub2 · Cited by 153
Helleberg, M., Niemann, C. U., Moestrup, K. S., Kirk, O., Lebech, A., Lane, C., & Lundgren, J. D. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa446 · Cited by 144
Long, S. W., Olsen, R. J., Christensen, P. A., Bernard, D. W., Davis, J. J., Shukla, M. P., Nguyen, M., Saavedra, M. O., Yerramilli, P., Pruitt, L., et al. (2020) · mBio · doi:10.1128/mbio.02707-20 · Cited by 145
The mechanism of RNA capping by SARS-CoV-2
Park, G. J., Osinski, A., Hernandez, G., Eitson, J. L., Majumdar, A., Tonelli, M., Henzler‐Wildman, K. A., Pawłowski, K., Chen, Z., Li, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05185-z · Cited by 146
Quesada‐Gómez, J. M., Castillo, M. E., & Bouillon, R. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105719 · Cited by 151
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Rosenke, K., Hansen, F., Schwarz, B. H., Feldmann, F., Haddock, E., Rosenke, R., Barbian, K., Meade-White, K. D., Okumura, A., Leventhal, S. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22580-8 · Cited by 145
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment
Karoui, K. E., & Vriese, A. S. D. (2022) · Kidney International · doi:10.1016/j.kint.2022.01.022 · Cited by 150
IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
Atal, S., & Fatima, Z. (2020) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00342-z · Cited by 150
Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies
Costa, F. F., Rosário, W. R., Farias, A. C. R., de Souza, R. G., Gondim, R. S. D., & Barroso, W. A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.06.016 · Cited by 147
The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)
Domingo, P., Mur, I., Pomar, V., Corominas, H., Casademont, J., & Benito, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102887 · Cited by 174
SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation
Keyhanian, K., Umeton, R. P., Mohit, B., Davoudi, V., Hajighasemi, F., & Ghasemi, M. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577436 · Cited by 148
Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020
Finelli, L., Gupta, V., Petigara, T., Yu, K. C., Bauer, K. A. A., & Puzniak, L. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6556 · Cited by 143
Nanotechnology-based strategies against SARS-CoV-2 variants
Huang, X., Kon, E., Han, X., Zhang, X., Kong, N., Mitchell, M. J., Peer, D., & Tao, W. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01174-5 · Cited by 146
RECOVERY Collaborative Group, Horby, P., Mafham, M. M., Peto, L., Campbell, M. R., Pessoa-Amorim, G., Spata, E., Staplin, N., Emberson, J., Prudon, B., et al. (2021) · medRxiv · doi:10.1101/2021.06.15.21258542 · Cited by 170
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I. O., Akdiş, M., Alves‐Correia, M., Antó, J. M., Arcolacı, A., Azkur, A. K., Azkur, D., et al. (2020) · Allergy · doi:10.1111/all.14449 · Cited by 140
COVID-19 and the Kidneys: An Update
Benedetti, C., Waldman, M. A., Zaza, G., Riella, L. V., & Cravedi, P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00423 · Cited by 145
Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy
Jiang, Y.-Z., Rubin, L., Peng, T., Liu, L., Xing, X., Lazarovici, P., & Zheng, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59272 · Cited by 144
Cell response analysis in SARS-CoV-2 infected bronchial organoids
Sano, E., Suzuki, T., Hashimoto, R., Itoh, Y., Sakamoto, A., Sakai, Y., Saito, A., Okuzaki, D., Motooka, D., Muramoto, Y., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03499-2 · Cited by 137
Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase
Zandi, K., Musall, K., Oo, A., Cao, D., Liang, B., Hassandarvish, P., Lan, S., Slack, R. L., Kirby, K. A., Bassit, L., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9050893 · Cited by 144
COVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 143
Sahoo, B. M., Kumar, B. V. V. R., Sruti, J., Mahapatra, M. K., Banik, B. K., & Borah, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.628144 · Cited by 146
Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication
Chu, J., Xing, C., Du, Y., Duan, T., Liu, S., Zhang, P., Cheng, C., Henley, J. E., Liu, X., Chen, Q., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00479-4 · Cited by 138
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T., Fukuhara, T., Ichihashi, G., Sanaki, T., Baba, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00697-22 · Cited by 137
“hospitalized with COVID-19, with an acceptable safety profile (11).”
BackgroundUtilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges
Parvathaneni, V., & Gupta, V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118275 · Cited by 138
Arafet, K., Serrano-Aparicio, N., Lodola, A., Mulholland, A. J., González, F. V., Świderek, K., & Moliner, V. (2020) · Chemical Science · doi:10.1039/d0sc06195f · Cited by 141
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
Li, Y., Cao, L., Li, G., Cong, F., Li, Y., Sun, J., Luo, Y., Chen, G., Li, G., Wang, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01929 · Cited by 138
Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety
Breining, P., Frølund, A. L., Højen, J. F., Gunst, J. D., Stærke, N. B., Sædder, E. A., Cases, M., Little, P. S., Nielsen, L. P., Søgaard, O. S., et al. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13533 · Cited by 141
Calming the cytokine storm in COVID-19
Cron, R. Q., Caricchio, R., & Chatham, W. W. (2021) · Nature Medicine · doi:10.1038/s41591-021-01500-9 · Cited by 136
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Kneller, D. W., Li, H., Phillips, G., Weiss, K. L., Zhang, Q., Arnould, M. A., Jonsson, C. B., Surendranathan, S., Parvathareddy, J., Blakeley, M. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29915-z · Cited by 140
Two Years into the COVID-19 Pandemic: Lessons Learned
da Silva, S. J. R., do Nascimento, J. C. F., Mendes, R. P. G., Guarines, K. M., da Silva, C. T. A., da Silva, P. G., de Magalhães, J. J. F., Vigar, J. R. J., Silva‐Júnior, A., Kohl, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00204 · Cited by 155
Mikulska, M., Sepulcri, C., Dentone, C., Magnè, F., Balletto, E., Baldi, F., Labate, L., Russo, C., Mirabella, M., Magnasco, L., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad181 · Cited by 139
Impact of COVID-19 in solid organ transplant recipients
Danziger‐Isakov, L. A., Blumberg, E. A., Manuel, O., & Sester, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16449 · Cited by 139
Tang, X., Feng, Y., Ni, J.-X., Zhang, J.-Y., Liu, L.-M., Hu, K., Wu, X., Zhang, J.-X., Chen, J.-W., Zhang, J.-C., et al. (2021) · Respiration · doi:10.1159/000512063 · Cited by 133
Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)
Verma, S., Twilley, D., Esmear, T., Oosthuizen, C. B., Reid, A.-M., Cuyler, M., & Lall, N. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.561334 · Cited by 137
SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress
Chang, R. P., Mamun, A., Dominic, A., & Le, N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.605908 · Cited by 136
Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
Khoury, D. S., Wheatley, A. K., Ramuta, M. D., Reynaldi, A., Cromer, D., Subbarao, K., O’Connor, D. H., Kent, S. J., & Davenport, M. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00471-1 · Cited by 115
Use of convalescent plasma in hospitalized patients with COVID-19: case series
Hegerova, L. T., Gooley, T. A., Sweerus, K. A., Maree, C. L., Bailey, N., Bailey, M., Dunleavy, V., Patel, K., Alcorn, K. W., Haley, R., et al. (2020) · Blood · doi:10.1182/blood.2020006964 · Cited by 133
The place for remdesivir in COVID-19 treatment
Young, B. E., Tan, T. T., & Leo, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30911-7 · Cited by 133
Humeniuk, R., Mathias, A. A., Kirby, B. J., Lutz, J. D., Cao, H., Osinusi, A. O., Babusis, D. M., Porter, D., Wei, X., Ling, J. R., et al. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-00984-5 · Cited by 133
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19
Bellan, M., Baricich, A., Patrucco, F., Zeppegno, P., Gramaglia, C. M., Balbo, P. E., Carriero, A., Amico, C. S., Avanzi, G. C., Barini, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01215-4 · Cited by 140
Rivera, D. R. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., Lopes, G. D. L., Jr., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0941 · Cited by 135
Gharebaghi, N., Nejadrahim, R., Mousavi, S. J., Sadat‐Ebrahimi, S., & Hajizadeh, R. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05507-4 · Cited by 132
COVID-19: In the Eye of the Cytokine Storm
de la Rica, R., Borges-Sa, M., & González‐Freire, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.558898 · Cited by 134
Wei, Y., & Shah, R. (2020) · Pharmaceuticals · doi:10.3390/ph13070155 · Cited by 140
Remdesivir is a Delayed Translocation Inhibitor of SARS CoV-2 Replication
Bravo, J. P. K., Dangerfield, T. L., Taylor, D. W., & Johnson, K. A. (2020) · Molecular Cell · doi:10.1016/j.molcel.2021.01.035 · Cited by 134
Barnes, E. J., Goodyear, C. S., Willicombe, M. K., Gaskell, C., Siebert, S., de Silva, T. I., Murray, S. M., Rea, D. W., Snowden, J. A., Carroll, M. W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02414-4 · Cited by 132
Kaeuffer, C., Hyaric, C. L., Fabacher, T., Mootien, J., Dervieux, B., Ruch, Y., Hugerot, A., Zhu, Y.-J., Pointurier, V., Clère-Jehl, R., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.48.2000895 · Cited by 130
Good, S. S., Westover, J. B., Jung, K., Zhou, X.-J., Moussa, A. M., Colla, P. L., Collu, G., Canard, B., & Sommadossi, J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02479-20 · Cited by 128
Bepridil is potent against SARS-CoV-2 in vitro
Vatansever, E. C., Yang, K. S., Drelich, A. K., Kratch, K. C., Cho, C.-C., Rayavara, K., Hsu, J. C., Mellott, D. M., Xu, S., Tseng, C.-T. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012201118 · Cited by 130
Liu, Y., Qin, C., Rao, Y., Ngo, C., Feng, J. J., Zhao, J., Zhang, S. J., Wang, T., Carrière, J., Savas, A. C., et al. (2021) · mBio · doi:10.1128/mbio.02335-21 · Cited by 135
Phosphatidylserine receptors enhance SARS-CoV-2 infection
Bohan, D., Ert, H. A. V., Ruggio, N., Rogers, K. J., Badreddine, M., Aguilar-Briseño, J. A., Elliff, J. M., Chávez, R. A. R., Gao, B., Stokowy, T., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009743 · Cited by 132
Sourimant, J., Lieber, C. M., Aggarwal, M., Cox, R. M., Wolf, J. D., Yoon, J.-J., Toots, M., Ye, C., Sticher, Z. M., Kolykhalov, A. A., et al. (2022) · Science · doi:10.1126/science.abj5508 · Cited by 130
Brendish, N. J., Poole, S., Naidu, V. V., Mansbridge, C., Norton, N., Wheeler, H., Presland, L., Kidd, S. P., Cortes, N., Borca, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30454-9 · Cited by 129
Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity
Kvedaraite, E., Hertwig, L., Sinha, I., Ponzetta, A., Myrberg, I. H., Lourda, M., Dzidic, M., Akber, M., Klingström, J., Folkesson, E., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018587118 · Cited by 128
Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19
Vahedifard, F., & Chakravarthy, K. V. (2021) · Emergent Materials · doi:10.1007/s42247-021-00168-8 · Cited by 129
Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management
Aslan, A., Aslan, C., Zolbanin, N. M., & Jafari, R. (2021) · Pneumonia · doi:10.1186/s41479-021-00092-9 · Cited by 144
Alwazeer, D., Liu, F. F.-C., Wu, X. Y., & LeBaron, T. W. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5513868 · Cited by 128
Immunological memory to SARS-CoV-2 assessed for up to eight months after infectionPreprint
Dan, J., Mateus, J., Kato, Y., Hastie, K., Yu, E., Faliti, C. E., Grifoni, A., Ramirez, S., Haupt, S., Frazier, A., et al. (2020) · bioRxiv · doi:10.1101/2020.11.15.383323 · Cited by 147
Karampela, Ι., & Dalamaga, Μ. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.06.004 · Cited by 127
Khadke, S., Ahmed, N., Ahmed, N., Ratts, R., Raju, S., Gallogly, M. M., Lima, M. J. G. D., & Sohail, M. R. (2020) · Virology Journal · doi:10.1186/s12985-020-01415-w · Cited by 127
Bai, C., Chotirmall, S. H., Rello, J., Alba, G. A., Ginns, L. C., Krishnan, J. A., Rogers, R., Bendstrup, E. M., Burgel, P., Chalmers, J. D., et al. (2020) · European Respiratory Review · doi:10.1183/16000617.0287-2020 · Cited by 130
COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges
Pathania, A. S., Prathipati, P., Abdul, B. A., Chava, S. P., Katta, S. S., Gupta, S. C., Gangula, P. R., Pandey, M. K., Durden, D. L., Byrareddy, S. N., et al. (2020) · Theranostics · doi:10.7150/thno.51471 · Cited by 131
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
Vicenti, I., Zazzi, M., & Saladini, F. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1880568 · Cited by 129
Amstutz, A., Speich, B., Mentré, F., Rueegg, C. S., Belhadi, D., Assoumou, L., Burdet, C., Murthy, S., Dodd, L. E., Wang, Y., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00528-8 · Cited by 129
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19
Yotsuyanagi, H., Ohmagari, N., Doi, Y., Yamato, M., Bắc, N. H., Cha, B. K., Imamura, T., Sonoyama, T., Ichihashi, G., Sanaki, T., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.54991 · Cited by 128
Ko, M., Jeon, S., Ryu, W., & Kim, S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26397 · Cited by 126
Pfortmueller, C. A., Spinetti, T., Urman, R. D., Luedi, M. M., & Schefold, J. C. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.12.011 · Cited by 135
Razonable, R. R., Pawlowski, C., O’Horo, J. C., Arndt, L. L., Arndt, R. F., Bierle, D. M., Borgen, M. J. D., Hanson, S. N., Hedin, M. C., Lenehan, P. J., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101102 · Cited by 125
Autophagy in health and disease: From molecular mechanisms to therapeutic target
Lu, G. X., Wang, Y., Shi, Y. P., Zhang, Z., Huang, C., He, W., Wang, C., & Shen, H. (2022) · MedComm · doi:10.1002/mco2.150 · Cited by 135
Kaptein, F. H. J., Stals, M. A. M., Grootenboers, M., Braken, S. J. E., Burggraaf, J. L. I., van Bussel, B. C. T., Cannegieter, S. C., Cate, H. T., Endeman, H., Gommers, D. A. M. P. J., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.019 · Cited by 124
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Iketani, S., Forouhar, F., Liu, H., Hong, S. J., Lin, F.-Y., Nair, M. S., Zask, A., Huang, Y., Li, X., Stockwell, B. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22362-2 · Cited by 125
Rosas, I. O., Diaz, G., Gottlieb, R., Lobo, S. M., Robinson, P., Hunter, B. D., Cavalcante, A. J. W., Overcash, J. S., Hanania, N. A., Skarbnik, A. P. Z., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06507-x · Cited by 123
Impact of COVID-19 on Cardiovascular Disease
Vosko, I., Zirlik, A., & Bugger, H. (2023) · Viruses · doi:10.3390/v15020508 · Cited by 139
Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications
Faruqui, S., Okoli, F. C., Olsen, S. K., Feldman, D. M., Kalia, H. S., Park, J. S., Stanca, C. M., Diaz, V. F., Yuan, S., Dagher, N. N., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001264 · Cited by 124
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
Arribas, J. R., Bhagani, S., Lobo, S. M., Хаертынова, И. М., Mateu, L., Fishchuk, R., Park, W. Y., Hussein, K., Kim, S. W., Ghosn, J., et al. (2021) · NEJM Evidence · doi:10.1056/evidoa2100044 · Cited by 129
Metadata
- Authors
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., Lye, D. C., Ohmagari, N., Oh, M.-D., Ruiz-Palacios, G. M., Benfield, T., Fätkenheuer, G., Kortepeter, M. G., Atmar, R. L., Creech, C. B., Lundgren, J., Babiker, A. G., Pett, S., Neaton, J. D., Burgess, T. H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S., & Lane, H. C.
- Affiliations
- National Institutes of Health (US)
- From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) — all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical...
- Corresponding author
- Beigel, John H.
- ORCID
- Beigel, John H.
- Dodd, Lori E.
- Mehta, Aneesh K.
- Zingman, Barry S.
- Kalil, Andre C.
- Hohmann, Elizabeth
- Chu, Helen Y.
- Luetkemeyer, Annie
- Kline, Susan
- Finberg, Robert W.
- Dierberg, Kerry
- Tapson, Victor
- Patterson, Thomas F.
- Paredes, Roger
- Short, William R.
- Touloumi, Giota
- Lye, David Chien
- Ohmagari, Norio
- Oh, Myoung-don
- Ruiz-Palacios, Guillermo M.
- Benfield, Thomas
- Fätkenheuer, Gerd
- Atmar, Robert L.
- Creech, C. Buddy
- Lundgren, Jens
- Babiker, Abdel G.
- Pett, Sarah
- Neaton, James D.
- Burgess, Timothy H.
- Bonnett, Tyler
- Makowski, Mat
- Nayak, Seema
- Lane, H. Clifford
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-11-05
- Volume
- 383
- Issue
- 19
- Pages
- 1813-1826
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7262788
- OpenAlex
- W3027630905
- Cited by
- 7,267
- References
- 22
- Citations by year
- 2026: 146 · 2025: 324 · 2024: 518 · 2023: 901 · 2022: 1447 · 2021: 2475 · 2020: 1451
- FWCI
- 206.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- eScholarship@McGill (McGill) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Cancer Institute (HHSN261200800001E, HHSN261201500003I)
- National Institute of Allergy and Infectious Diseases (UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148575, UM1AI148576, UM1AI148684, UM1AI148685, UM1AI148689)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Keywords
- remdesivir, COVID-19 pandemic, SARS-CoV-2, antiviral therapy, hospitalized patients, lower respiratory tract infection, time to recovery, mortality, serious adverse events, clinical improvement, treatment efficacy, SARS-CoV-2 RNA load, viral load reduction, disease severity, prognostic factors, prognostic score
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adenosine Monophosphate, Adult, Aged, Alanine, Antiviral Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Oxygen Inhalation Therapy, Pneumonia, Viral, Respiration, Artificial, Time Factors, Extracorporeal Membrane Oxygenation, Coronavirus Infections, Kaplan-Meier Estimate, Young Adult, Pandemics, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
